JP5378222B2 - タンパク質キナーゼ調節物質としての二環式トリアゾール - Google Patents

タンパク質キナーゼ調節物質としての二環式トリアゾール Download PDF

Info

Publication number
JP5378222B2
JP5378222B2 JP2009533541A JP2009533541A JP5378222B2 JP 5378222 B2 JP5378222 B2 JP 5378222B2 JP 2009533541 A JP2009533541 A JP 2009533541A JP 2009533541 A JP2009533541 A JP 2009533541A JP 5378222 B2 JP5378222 B2 JP 5378222B2
Authority
JP
Japan
Prior art keywords
group
substituted
unsubstituted
alkyl
pyridinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009533541A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010507578A (ja
JP2010507578A5 (enExample
Inventor
ピエール−イヴ・ブーノー
クリストファー・ロナルド・スミス
エリザベス・アン・ジェファーソン
Original Assignee
エスジーエックス ファーマシューティカルズ、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスジーエックス ファーマシューティカルズ、インコーポレイテッド filed Critical エスジーエックス ファーマシューティカルズ、インコーポレイテッド
Publication of JP2010507578A publication Critical patent/JP2010507578A/ja
Publication of JP2010507578A5 publication Critical patent/JP2010507578A5/ja
Application granted granted Critical
Publication of JP5378222B2 publication Critical patent/JP5378222B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2009533541A 2006-10-23 2007-10-18 タンパク質キナーゼ調節物質としての二環式トリアゾール Expired - Fee Related JP5378222B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US86255206P 2006-10-23 2006-10-23
US60/862,552 2006-10-23
US87030906P 2006-12-15 2006-12-15
US60/870,309 2006-12-15
US91376607P 2007-04-24 2007-04-24
US60/913,766 2007-04-24
US95284007P 2007-07-30 2007-07-30
US60/952,840 2007-07-30
PCT/US2007/081841 WO2008051808A2 (en) 2006-10-23 2007-10-18 Bicyclic triazoles as protein kinase modulators

Publications (3)

Publication Number Publication Date
JP2010507578A JP2010507578A (ja) 2010-03-11
JP2010507578A5 JP2010507578A5 (enExample) 2010-12-02
JP5378222B2 true JP5378222B2 (ja) 2013-12-25

Family

ID=38956385

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009533541A Expired - Fee Related JP5378222B2 (ja) 2006-10-23 2007-10-18 タンパク質キナーゼ調節物質としての二環式トリアゾール

Country Status (25)

Country Link
US (1) US8507489B2 (enExample)
EP (1) EP2084162B1 (enExample)
JP (1) JP5378222B2 (enExample)
KR (1) KR20090071612A (enExample)
AR (1) AR063520A1 (enExample)
AU (1) AU2007309149C1 (enExample)
BR (1) BRPI0717320A2 (enExample)
CA (1) CA2667428A1 (enExample)
CO (1) CO6190620A2 (enExample)
CR (1) CR10803A (enExample)
DK (1) DK2084162T3 (enExample)
EA (1) EA200970403A1 (enExample)
ES (1) ES2393130T3 (enExample)
IL (1) IL197958A0 (enExample)
MA (1) MA30871B1 (enExample)
MX (1) MX2009004059A (enExample)
NO (1) NO20091618L (enExample)
NZ (1) NZ575336A (enExample)
PE (1) PE20080893A1 (enExample)
PL (1) PL2084162T3 (enExample)
PT (1) PT2084162E (enExample)
SV (1) SV2009003235A (enExample)
TN (1) TN2009000142A1 (enExample)
TW (1) TW200835492A (enExample)
WO (1) WO2008051808A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EP2165710A1 (en) * 2008-09-19 2010-03-24 Institut Curie Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
EP2356116A1 (en) 2008-11-20 2011-08-17 OSI Pharmaceuticals, Inc. Substituted pyrroloý2,3-b¨-pyridines and-pyrazines
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
IN2012DN01453A (enExample) 2009-08-20 2015-06-05 Novartis Ag
PT3511330T (pt) 2009-12-31 2020-12-24 Hutchison Medipharma Ltd Intermediário sintético útil na preparação de inibidores de triazolopiridina c-met
US20130072495A1 (en) 2010-05-14 2013-03-21 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
AR085183A1 (es) 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
UY33549A (es) * 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolil aminas como agentes inhibidores de las quinasas
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
JP6106603B2 (ja) 2011-01-11 2017-04-05 スノビオン プハルマセウトイカルス インコーポレイテッド ヘテロアリール化合物及びその使用方法
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
CA2866321A1 (en) 2012-04-03 2013-10-10 Novartis Ag Tyrosine kinase inhibitor combinations and their use
MX371119B (es) 2012-04-03 2020-01-17 Novartis Ag Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
WO2014089904A1 (en) 2012-12-10 2014-06-19 Abbvie Inc. Triazinone compounds
US20150174034A1 (en) 2013-03-13 2015-06-25 Avon Products, Inc. Tyrosinase inhibitors
US9303043B2 (en) * 2013-03-13 2016-04-05 Greentech, Inc. Process for making benzoxazepin compounds
WO2014164195A1 (en) 2013-03-13 2014-10-09 Avon Products, Inc Tyrosinase inhibitors
WO2014158943A1 (en) * 2013-03-13 2014-10-02 Avon Products, Inc Tyrosinase inhibitors
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
WO2014180182A1 (zh) * 2013-05-10 2014-11-13 江苏豪森药业股份有限公司 [1,2,4]三唑并[4,3-a]吡啶类衍生物，其制备方法或其在医药上的应用
WO2017049711A1 (zh) 2015-09-24 2017-03-30 上海海聚生物科技有限公司 喹啉类衍生物、其药物组合物、制备方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604091A (en) 1984-03-01 1997-02-18 Microgenics Corporation Methods for protein binding enzyme complementation
JPS60194443A (ja) * 1984-03-16 1985-10-02 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
JPS62228086A (ja) * 1985-12-23 1987-10-06 Takeda Chem Ind Ltd セフエム化合物
EP0228061A3 (en) * 1985-12-23 1988-12-14 Takeda Chemical Industries, Ltd. Cephem compounds
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
US6960584B2 (en) * 2001-04-10 2005-11-01 Merck & Co., Inc. Inhibitors of Akt activity
WO2002083139A1 (en) * 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
US20030229453A1 (en) 2002-04-09 2003-12-11 Antonysamy Stephen Suresh Crystals and structures of PAK4KD kinase PAK4KD
AU2003297161B8 (en) * 2002-12-18 2011-03-31 Vertex Pharmaceuticals Incorporated Triazolopyridazines as protein kinases inhibitors
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
US7452993B2 (en) * 2004-07-27 2008-11-18 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
CA2577937C (en) 2004-08-26 2010-12-21 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
EP1830853B1 (en) 2004-12-27 2011-08-10 Novartis AG Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases

Also Published As

Publication number Publication date
EP2084162A2 (en) 2009-08-05
PL2084162T3 (pl) 2013-01-31
CR10803A (es) 2009-06-16
KR20090071612A (ko) 2009-07-01
CO6190620A2 (es) 2010-08-19
PT2084162E (pt) 2012-10-09
JP2010507578A (ja) 2010-03-11
AU2007309149C1 (en) 2013-04-04
CA2667428A1 (en) 2008-05-02
TW200835492A (en) 2008-09-01
NZ575336A (en) 2012-04-27
AU2007309149A1 (en) 2008-05-02
TN2009000142A1 (en) 2010-10-18
WO2008051808A2 (en) 2008-05-02
EA200970403A1 (ru) 2009-10-30
MA30871B1 (fr) 2009-11-02
AR063520A1 (es) 2009-01-28
WO2008051808A3 (en) 2008-07-24
DK2084162T3 (da) 2012-10-01
AU2007309149B2 (en) 2012-09-06
ES2393130T3 (es) 2012-12-18
US8507489B2 (en) 2013-08-13
SV2009003235A (es) 2009-10-15
PE20080893A1 (es) 2008-08-26
MX2009004059A (es) 2009-04-27
NO20091618L (no) 2009-05-22
BRPI0717320A2 (pt) 2013-10-22
IL197958A0 (en) 2009-12-24
US20090258855A1 (en) 2009-10-15
EP2084162B1 (en) 2012-09-12

Similar Documents

Publication Publication Date Title
JP2010507578A (ja) タンパク質キナーゼ調節物質としての二環式トリアゾール
KR101083177B1 (ko) 트리아졸로-피리다진 단백질 키나제 조정제
JP7095052B2 (ja) Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法
US10858365B2 (en) Triazolo-pyrimidine compounds and uses thereof
US20190152949A1 (en) Therapeutic compounds and uses thereof
TW202039489A (zh) Mat2a之雜雙環抑制劑及用於治療癌症之使用方法
CN101558070A (zh) 三唑并哒嗪蛋白激酶调节剂
US20140080799A1 (en) Aminopyrimidine Kinase Inhibitors
US20110275762A1 (en) Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes
CN107108648A (zh) 作为ERK抑制剂的噻吩并[2,3‑c]吡咯‑4‑酮衍生物
KR20190013721A (ko) Tam 저해제로서의 피롤로트리아진 화합물
WO2015038417A1 (en) Compounds for regulating fak and/or src pathways
JP2010528991A (ja) 複素環式キナーゼ調節因子
KR20220085735A (ko) 아이소옥사졸리딘 유도체 화합물 및 이의 용도
CN111689991B (zh) 取代的杂芳基化合物及其组合物和用途
CN103748095B (zh) 二环杂芳族化合物
AU2023380028A1 (en) Pyridone and pyrimidinone inhibitors of hematopoietic progenitor kinase 1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130122

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130329

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130925

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees